HLTRF
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.07 | $13M | $6M |
| 2025 Q4 | -0.04 | $15M | $6M |
| 2025 Q3 | -0.12 | $14M | $2M |
| 2025 Q2 | -0.09 | $14M | $4M |
| 2025 Q1 | -0.14 | $13M | $4M |
| 2024 Q4 | -0.09 | $16M | $3M |
| 2024 Q3 | -0.15 | $14M | $2M |
| 2024 Q2 | -0.18 | $15M | $3M |